PTC Therapeutics (NASDAQ:PTCT) Trading Down 6.5% on Disappointing Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) shares traded down 6.5% on Friday following a dissappointing earnings announcement. The stock traded as low as $66.48 and last traded at $65.3310. 212,432 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,217,086 shares. The stock had previously closed at $69.90.

The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue was down 22.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.85) earnings per share.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Strong commercial uptake: management highlighted rapid Sephience (sepiapterin) adoption with Q4 revenue of $92M and 2025 Sephience revenue of $111M, and full‑year 2025 product & royalty revenue of $831M (above prior guidance). Read More.
• Positive Sentiment: Strong liquidity: PTC reported approximately $1.95B of cash as of Dec. 31, 2025, supporting R&D and commercialization even after near‑term revenue weakness. Read More.
• Neutral Sentiment: Analyst view: Bank of America trimmed its price target from $97 to $93 but maintained a Buy rating — the new PT still implies meaningful upside from current levels, which could support the stock if execution improves. Read More.
• Neutral Sentiment: Earnings call color: company commentary and call highlights may include forward product trends and pipeline updates that investors will parse for offsets to the headline miss. Read More.
• Negative Sentiment: Big Q4 miss: PTCT reported a loss of $1.67/sh vs. consensus -$0.21 and revenue of $164.7M vs. $281.5M expected; revenue fell ~22.7% YoY — headline results pushed investor selling. Read More.
• Negative Sentiment: Weaker FY‑2026 guidance: the company issued revenue guidance of $700M–$800M vs. consensus ~$974M, widening the gap to Street estimates and weighing on forward expectations. Read More.
• Negative Sentiment: Regulatory overhang: reporting flagged new questions after the Translarna NDA withdrawal, adding uncertainty around that program and potential future regulatory setbacks. Read More.
• Negative Sentiment: Insider selling: a company VP sold ~5,894 shares in mid‑Feb (two filings), modestly reducing holdings — insider sales can amplify negative sentiment following a weak print. Read More.

Analysts Set New Price Targets

PTCT has been the topic of several recent analyst reports. Jefferies Financial Group boosted their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. The Goldman Sachs Group lifted their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. TD Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $68.00 to $119.00 in a research report on Tuesday, January 27th. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $80.73.

Insider Buying and Selling

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $213,698.16. Following the completion of the sale, the vice president owned 108,231 shares of the company’s stock, valued at $7,506,902.16. This trade represents a 2.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Pauwels sold 1,024 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $78.70, for a total transaction of $80,588.80. Following the completion of the transaction, the insider directly owned 80,141 shares in the company, valued at $6,307,096.70. This trade represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 276,765 shares of company stock worth $21,903,948. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. bought a new stake in shares of PTC Therapeutics in the 4th quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its stake in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares during the last quarter. Optiver Holding B.V. grew its position in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 249 shares in the last quarter. Comerica Bank increased its stake in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of PTC Therapeutics during the 4th quarter worth $41,000.

PTC Therapeutics Trading Down 6.1%

The business’s fifty day moving average price is $75.01 and its two-hundred day moving average price is $67.78. The firm has a market cap of $5.27 billion, a P/E ratio of 7.65 and a beta of 0.48.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.